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Abstract  
 
Background: Ziprasidone (ZIP) is often used with olanzapine (OLZ) in ‘switch’ and 
combination therapy but empirical evidence to support these strategies is limited.  
Objective: This study was therefore designed to compare the efficacy and tolerability of 
switching from OLZ to ZIP, the combination of both medications, and OLZ and ZIP 
monotherapy, in patients with schizophrenia spectrum disorders (SSD).  
Methods: In this 12 week open-label, assessor-blinded randomized trial, 148 patients 
with SSD who had not used antipsychotics for at least 3 months were assigned to ZIP (n 
= 49) or OLZ monotherapy (n = 31); OLZ for 4 weeks then a switch to ZIP (OLZ/ZIP, n 
= 35); or combination therapy (OLZ+ZIP, n = 33). The severity of psychosis and 
abnormal involuntary movements was evaluated at baseline, 1, 2, 4, 8, and 12 weeks 
using standard instruments. Baseline-to-endpoint changes in weight gain and metabolic 
measures were compared.  
Results: The efficacy of both OLZ/ZIP and OLZ+ZIP was comparable OLZ 
monotherapy and better than ZIP monotherapy in reducing overall psychotic and 
negative symptoms at most 8 and 12 week measurement points. Changes in weight gain, 
glucose, and lipid measures did not differ between OLZ/ZIP and OLZ+ZIP, but were 
markedly higher following OLZ monotherapy. The OLZ+ZIP group had the lowest 
overall incidence of adverse events and extrapyramidal symptoms of all the treatment 
regimens.  
Conclusions: We conclude that combining ZIP and OLZ at the outset of treatment is 
superior to switching from OLZ to ZIP in terms of improving psychotic symptoms and 
limiting movement side effects without increasing the risk of metabolic syndrome.   
 
Keywords: ziprasidone; olanzapine; switching therapy; Combination therapy; metabolic 
syndrome; schizophrenia spectrum disorders    
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1. Introduction 
 
Although the availability of newer antipsychotic agents has greatly extended treatment 
options for psychotic disorders, it has failed to reduce the incidence of adverse drug 
reactions (Miyamoto et al., 2012). In contrast, atypical antipsychotics may even increase 
the risk of some adverse effects, in particular metabolic and movement disorders 
(Miyamoto et al., 2012). Optimizing antipsychotic treatment regimens through ‘switch’ 
and combination strategies may potentially achieve a balance between the therapeutic 
benefits and adverse effect risk, but direct evidence for these approaches is limited.  
 
Olanzapine (OLZ) and ziprasidone (ZIP) are commonly used atypical agents with 
documented efficacy for the treatment of psychotic and manic disorders (Sikich, 2008), 
however, they have different therapeutic and side effect profiles (Mauri et al., 2014). In 
psychosis, OLZ treatment produces significantly greater symptom improvement, higher 
response rates and better completion rates compared to ZIP treatment (Breier et al., 2005; 
Grootens et al., 2011; Kinon et al., 2006; Simpson et al., 2004; Ou et al., 2013). OLZ 
therapy has also been reported to cause fewer extrapyramidal symptoms than ZIP 
(Breier et al., 2005). However, compared to ZIP, OLZ is associated with an increased 
risk of developing metabolic syndrome, manifesting as weight gain, dyslipidemia, 
glucose intolerance, and insulin resistance, leading to diabetes mellitus and 
cardiovascular disorders (Breier et al., 2005; Grootens et al., 2011; Kinon et al., 2006; 
Simpson et al., 2004; Ou et al., 2013). This has led to the proposition that combining 
these agents would improve efficacy and reduce adverse side effects of antipsychotic 
treatment.  
 
Over the past decade, numerous studies have demonstrated that a switch to ZIP from 
other antipsychotic medications may limit the weight gain and other metabolic adverse 
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effects of treatment (Alptekin et al., 2009; Chen et al., 2012; Harvey et al., 2004; Lee et 
al., 2013; Rossi et al., 2008; Simpson et al., 2008; Weiden et al., 2003a,b). In contrast, 
there has been only one pilot trial of a combination therapy of ZIP and OLZ, and this did 
not find additional benefits of ZIP as an adjuvant in chronic schizophrenia (Henderson et 
al., 2009). To date, there are no published studies directly comparing the efficacy and 
tolerability of switch and combination therapy of ZIP and OLZ.   
 
In the present study we tested the hypothesis that combining ZIP and OLZ would 
produce better treatment outcomes compared to switching from OLZ to ZIP in 
schizophrenia spectrum disorders (SSD). To achieve this, we compared efficacy 
measures and tolerability in terms of metabolic and motor disturbances in drug-free 
patients with SSD started on one of four treatment regimens: OLZ and ZIP monotherapy, 
switching from OLZ to ZIP, and the combination of OLZ and ZIP. We adopted an open-
label, assessor-blinded randomized, parallel group design. 
 
2. Materials and methods 
 
2.1. Settings and participants 
This open-label, assessor-blinded, randomized parallel group study was conducted in the 
Department of Psychiatry at Xijing Hospital of Fourth Military University in Xi’an of 
China between October 2012 and October 2015. The study protocol was approved by 
the Medical Ethical Committee of Xijing Hospital of the Fourth Military Medical 
University and registered in www.chictr.org (ChiCTR-OPC-15007529), a member of the 
WHO International Clinical Trial Registry Platform. All outcomes, measures, and 
sample size were identified prior to study initiation and did not undergo modification 
thereafter. A detailed and full explanation of the study goal, treatment procedures, and 
potential side effects was presented to each patient and/or his/her guardians by 
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psychiatrists. All participants and/or their guardians gave voluntary, written, informed 
consent for their acceptance of the study. 
 
Inpatients who met the following criteria were eligible for participating in the study: (1) 
either gender aged 16-60 years; (2) had a diagnosis of SSD, including schizophrenia, 
schizoaffective disorder, schizophreniform disorder, and psychotic disorder not 
otherwise specified according to the Classification of Mental and Behavior Disorders 
(10th version) (ICD-10) (World Health Organization, 1992); (3) the severity of 
participants’ symptoms was at least moderate, as evidenced by the Positive and Negative 
Syndrome Scale (PANSS) total score of ≤?70 (Kay et al., 1987); and (4) had no 
antipsychotic treatment for at least 3 months at study entry.  
 
Subjects were excluded if they had: (1) serious comorbid cardiovascular, neurological, 
or other unstable medical conditions; (2) suicidal ideas or attempts or aggressive 
behavior; (3) laboratory tests of hepatic and renal function and/or electrocardiogram 
(ECG) beyond the normal reference ranges; (4) a history of alcoholism or drug abuse 
within the previous one year; (5) an investigational drug treatment within the previous 6 
months; (6) pre-existing diabetes mellitus; or (7) pregnant and lactation.  
 
2.2. Randomization and blinding 
Participants were randomly allocated to 1 of 4 groups: ZIP and OLZ monotherapy, 
switching from OLZ to ZIP, and the combination of the two drugs in an approximate 
ratio of 1.5:1:1:1. For randomization, simple, complete, non-sequential random codes 
were produced in advance using a computer-generated block scheme.  
 
The group allocation was done by the study coordinator (Y.H.B.) who was blind to 
participants’ treatment condition. Clinical assessors, drug dispenses, data collector and 
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analysts were also blind to patients’ medication status. Assessors and psychiatrists 
communicated with patients separately and were instructed not to acquire information 
about their other treatment conditions.  
 
2.3. Treatment procedures  
Orally administered OLZ dose in both mono- and combination therapy was initiated at 5 
mg/day and escalated to an optimal dose within 2 weeks based on individual patients’ 
response, with a maximum dose 20 mg/day. Orally administered ZIP in mono- and 
combination therapy was started at 80 mg/day and 40 mg/day, respectively, and titrated 
to a maximum of 160 mg/day within 2 weeks, depending on clinical and side effects. 
For switching therapy, OLZ was initiated at 5 mg/day; an optimal dose was achieved 
within 2 weeks and maintained to the end of 4 weeks. Tapering off OLZ was conducted 
from 5 weeks to 6 weeks. Over the same 2-week period, ZIP was given from an initial 
dose of 80 mg/day to a maximum of 160 mg/day. This switching regimen was designed 
based on our preliminary observation, which indicated that most patients’ conditions 
were well controlled following 3-4 weeks of OLZ treatment with an optimal dose.   
 
Concomitant use of other psychotropic drugs was generally not allowed. However, if 
clinically significant insomnia or extrapyramidal symptoms occurred that could 
potentially interfere with the continuation of experimental treatment, benzodiazepines 
(alprazolam or clonazepam), non-benzodiazepines (zolpidem or zopiclone), and anti- 
anticholinergic (trihexyphenidyl or injected scopolamine) agents were allowed only for 
acute use, without exceeding a cumulative duration of 14 days. Daily medications of 
each participant were monitored and recorded. Those who failed to maintain good 
medication compliance, defined as taking 80% or greater of the intended number of 
tablets, were removed from the study. 
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The prescription of medications was conducted by psychiatrists (W.H.H., H.N.W., 
Y.C.C., R.G.Z., and Q.R.T.) who were blind to clinical assessment results.    
 
2.4. Clinical assessment 
Clinical assessment was conducted at baseline, week 1, 2, 4, 8 and 12. Efficacy was 
measured using changes in scores on PANSS overall scales and subscales for positive, 
negative symptoms, and general psychopathology from the baseline to each time point. 
Safety and tolerability were assessed using the Treatment Emergent Symptom Scale 
(TESS) (Guy, 1976), with which all adverse events reported, elicited, or observed were 
recorded, including the date and time of onset, duration, severity, relationship with study 
drug, and action taken. The Extrapyramidal Symptom Rating Scale (ESRS) (Gharabawi 
et al., 2005) was used in addition to determine the incidence and severity of movement 
symptoms. Based on a maximum rating score on ESRS over the treatment period, the 
severity of extrapyramidal symptoms was categorized as none to mild (≤ 3), moderate (4
–8), and severe (≥ 9) levels.  
 
Clinical assessment was performed by assessors (M.C., Y. W., W.J.W., Y.H.Z., and 
L.G.) who were blind to patients’ medication conditions. To ensure consistency of 
assessment, a training workshop was carried out before the recruitment started. An inter-
rater reliability coefficient (κ value) of >0.80 on PANSS had been achieved from 
assessors involved in the study after the completion of training workshop. In most cases, 
all assessments of a subject from baseline to endpoint were conducted by the same 
assessor in order to minimize potential variations caused by different assessors.   
 
2.5. Metabolic measurement 
Body weight (kg), body mass index (BMI, kg/m2), and blood pressure were measured 
daily. Fasting glucose, triglycerides (TG), total cholesterol, high-density lipoprotein 
(HDL), and low-density lipoprotein (LDL) were measured at baseline and endpoints. 
The ratio of TG to HDL (TG/HDL) was calculated as an additional parameter, as it is a 
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sensitive measure of insulin resistance (Brehm et al., 2004). All blood samples were 
collected after an overnight fast and analyzed by the same clinical laboratory. Net or 
percent changes in metabolic variables from baseline to endpoint were used in data 
analysis. 
 
2.7. Statistical analysis 
Based on a previous study in schizophrenia (Breier et al., 2005), compared to ZI  
monotherapy, OLZ monotherapy should result in an additional approximately 8-point 
reduction in total PANSS score from baseline to 12 weeks, with an estimated standard 
deviation (SD) of 9. A sample size of 30 per group would therefore provide a greater 
than 90% power at significance level of 0.05.      
 
A linear mixed-effect model was applied to compare overall PANSS and its subscale 
scores based on the intention-to-treat population, defined as participants who completed 
baseline and at least one evaluation after treatment. The model was established using 
time and group as categorical fixed factors and random intercepts within a scaled 
identity covariance matrix. Age, sex and baseline total PANSS score were included as 
covariates. If differences in the slope among the 4 groups reached significance level, 
one-way analysis of variance (ANOVA) was used to further detect main effects, 
followed by Turkey test to detect between-group differences based on observed cases 
(OC), defined as the subset of subjects who had completed 12-week treatment and 
assessment per protocol. One-way ANOVA was also used to examine other continuous 
variables among the four groups. Categorical variables were analyzed using Chi-square 
(χ2) test. Statistical significance was defined as a two-tailed p < 0.05. The analysis was 
conducted with SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA).  
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3. Results 
 
3.1. Participant characteristics  
Of 987 patients screened, 148 were recruited and randomly assigned to the four groups 
as shown in flowchart (Fig. 1); 111 (75.0%) of them completed the full course of 
treatment and assessment (Fig. 1). The mean (SD) age of the whole sample was 26.9 (± 
6.4) years with the illness duration of 37.6 (±40.3) weeks, and the total PANSS score of 
79.6 (±11.4) was indicative of moderate to severe illness. Ninety-two (62.2%) patients 
were experiencing their first episode of psychosis and others had relapsed. The overall 
PANSS scores of OLZ/ZIP and OLZ+ZIP groups were significantly lower than the other 
two groups (F = 6.255, df = 3,144, p < 0.001); other baseline variables were not 
statistically different among the four groups (Table 1). Overall medication compliance 
was approximately 98% across the four groups. No patients were removed from the 
study due to poor compliance rate (<80%). The discontinuation rate due to lack of 
efficacy or exacerbation of symptoms was 24.5% (12/49) in ZIP monotherapy, which 
was strikingly higher than the other three groups (0-3.0%, χ2 = 91.309, df = 3, p < 0.001) 
(Fig. 1). 
 
The average doses of OLZ and ZIP given in the combination therapy were 
approximately 59% of the doses on monotherapy. The average OLZ dose on the 
switching therapy was 56.2% of the dose on OLZ monotherapy. The average ZIP doses 
were similar in the mono- and switching therapies (Table 2).  
 
3.2. Efficacy   
Changes from baseline in overall PANSS score and score on subscales are illustrated in 
Table 3 and Fig. 2. Linear mixed-effect model revealed significant differences in the 
slope among the four groups on total PANSS (F3,880 = 21.261, p < 0.0001), positive 
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(F3,880 = 24.830, p < 0.0001), negative symptoms (F3,880 = 87.207, p < 0.0001), and 
general psychopathology (F3,880  = 8.495, p < 0.0001). The four variables were 
significantly reduced over the course of treatment for each group (ZIP, F5,247 ≥ 24.116, p 
< 0.001; OLZ, F5,174 ≥ 16.605, p < 0.001; OLZ/ZIP, F5,184 ≥ 16.364, p < 0.001; 
OLZ+ZIP, F5,179 ≥ 12.077, p < 0.001). Treatment also produced a striking difference 
among the four groups in each variable (total PANSS, F3,801 = 5.226, p = 0.0014; 
positive symptoms, F3,801 = 9.298, p < 0.001; negative symptoms, F3,801 = 21.550, p 
<0.001; general psychopathology, F3,801 = 5.411, p = 0.0011). Between-group 
comparisons showed that the magnitude of reduction in PANSS total score and score on 
negative symptoms of the three OLZ-containing regimens was significantly greater than 
ZIP monotherapy at 8 and 12 weeks (adjusted p < 0.05), but not statistically significant 
between OLZ/ZIP and ZIP monotherapy at 12 weeks. OLZ/ZIP had a significantly 
greater improvement on negative symptoms than OLZ+ZIP at 1 week (adjusted p = 
0.013). OLZ monotherapy produced a markedly greater reduction in score on positive 
symptoms compared to ZIP alone and OLZ/ZIP at 12 weeks (adjusted p < 0.05), but did 
not differ significantly from OLZ+ZIP. No significantly statistical group differences in 
the general psychopathology subscale were observed between any groups at any 
measurement points.  
 
3.3. Weight and metabolic outcomes  
Net or percent baseline-to-endpoint changes in weight and metabolic variables are 
shown in Table 4. The three ZIP-containing regimens did not differ in weight gain and 
BMI, or percent changes in glucose, cholesterol, and TG/HDL; but patients on OLZ 
monotherapy had a much greater increase in these variables than did patients on the 
three ZIP-containing regimens (p ≤ 0.043).  
 
3.4. Adverse events 
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Table 5 summarizes the incidence of adverse events that occurred in at least 5% of the 
patients in any treatment group. The proportion of patients with ESRS-measured 
extrapyramidal symptoms, their extrapyramidal symptom severity, and the proportion of 
patients who needed to use hypnotics/anxiolytics for insomnia and anticholinergic 
agents for extrapyramidal symptoms are also included in the Table. OLZ+ZIP group had 
a significantly lower incidence of any adverse events (24.2% vs. 65.3%-80.0%, χ2 = 
25.683, df = 3, p < 0.001), muscle rigidity (3.0% vs. 28.6-32.3%, χ2 = 8.381, df = 3, p = 
0.039), and tremor (6.1% vs. 28.6%-36.7%, χ2 = 9.926, df = 3, p = 0.019) compared to 
the other three groups. The OLZ+ZIP group also had a significantly higher proportion of 
patients reporting ‘none’ and mild extrapyramidal symptoms (69.7% vs. 25.7%-48.4%) 
and much lower proportion with moderate (24.2% vs. 38.7%-57.1%) and severe 
symptoms (6.1% vs. 12.9%-18.4%) compared to the other three groups (χ2 = 16.649, p = 
0.011). There were no group differences in the proportion of participants who needed to 
use concomitant medication for their insomnia (χ2 = 1.198, df = 3, p = 0.754) and/or 
extrapyramidal symptoms (χ2 = 0.758, df = 3, p = 0.859).   
 
4. Discussion 
 
This is the first study to directly compare the efficacy and tolerability of switching from 
OLZ to ZIP with the combination of both, and also with OLZ and ZIP monotherapy in 
patients with SSD. Consistent with prior studies (Breier et al., 2005; Grootens et al., 
2011; Kinon et al., 2006; Simpson et al., 2004; Ou et al., 2013), the present study 
showed the superiority of OLZ over ZIP monotherapy in the control of psychotic 
episode of SSD. The OLZ-treated group had a greater reduction in total PANSS score 
and score on positive and negative subscales; whereas the ZIP-treated group had a 
higher discontinuation rate due to lack of efficacy or exacerbation of symptoms. 
Nevertheless, the three ZIP-containing regimens produced significantly less increase in 
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body weight, BMI, glucose, cholesterol, and TG/HDL ratio; so demonstrating 
advantages of ZIP over OLZ for metabolic adverse effects.  
 
Furthermore, the efficacy of OLZ/ZIP and OLZ+ZIP was comparable to that of OLZ 
monotherapy. Both were more efficacious than ZIP monotherapy in reducing overall 
psychotic and negative symptoms, suggesting that switching and combination of the two 
drugs indeed can provide additional benefits. This was more apparent in OLZ+ZIP 
regimen. OLZ+ZIP had equivalent efficacy to OLZ alone in reducing overall psychotic 
and positive symptoms at 12 weeks, but OLZ/ZIP did not. OLZ/ZIP was inferior to OLZ 
alone in controlling positive symptoms at 12 weeks, although it achieved greater 
improvement on negative symptoms in the first week. While both OLZ/ZIP and 
OLZ+ZIP had similar effects in limiting weight gain and the increase of several 
metabolic parameters, patients on OLZ+ZIP exhibited much lower overall incidence of 
adverse events. OLZ+ZIP also caused the least extrapyramidal side effects. These results 
clearly indicate that combining ZIP and OLZ produces better treatment outcomes than 
switching from OLZ to ZIP in terms of reducing psychotic symptoms and adverse side 
effects, in particular movement disturbance.   
 
Lower dosages of two antipsychotics have previously been suggested to cause fewer 
side effects than a high dosage of one antipsychotic (Kroken and Johnsen, 2012). In the 
present study, the average doses of both ZIP and OLZ used in OLZ+ZIP were only 
about 59% of those in monotherapy. Thus, the fewer adverse side effects observed in 
this study may, at least in part, be attributed to the lower dosages of the agents used. 
Similar results also have been observed in the combination of low-dosed clozapine and 
aripiprazole (Lim et al., 2004). It may also be possible that ZIP’s action as a partial 
agonist at the 5HT1A receptor (Mauri et al., 2014) limits weight gain and food intake by 
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counteracting the 5-HT2C antagonism which accompanies D2 receptor blockade by both 
OLZ and/or ZIP (Kirk et al., 2004; Kroeze et al., 2003; Snigdha et al., 2008).  
 
There are important differences between our study and previous studies of switching to 
ZIP. In those studies, the participants recruited were those who failed to achieve 
satisfactory response, had poor tolerability for metabolic side effects, or whose 
conditions had been stable under previous antipsychotic treatment (Alptekin et al., 2009; 
Chen et al., 2012; Harvey et al., 2004; Lee et al., 2013; Rossi et al., 2008; Simpson et al., 
2008; Weiden et al., 2003). In contrast, the participants in the present study had not used 
antipsychotic medications for at least 3 months and the majority of them were first-
episode subjects. This drug-free characteristic ensured that the results were not 
confounded by ‘carryover effects’ from previous antipsychotic treatment.  
 
Several limitations of the current study should be considered. First, the sample recruited 
for the current study was a subset of relatively young adults with SSD with a relatively 
short illness duration, rather than chronic schizophrenia. This demographically 
“homogeneous” feature should be considered and we cannot say whether our results 
generalize to other cohorts, especially older individuals and/or those with chronic illness.  
Second, we did not conduct longer-term follow-up comparison of OLZ/ZIP and 
OLZ+ZIP in the maintenance treatment of SSD. Only limited data are available on the 
efficacy and tolerability of long-term treatment following switch to ZIP (Chen et al., 
2012; Simpson et al., 2008), therefore the use of a combination of low-dose OLZ and 
ZIP for long-term maintenance treatment of schizophrenia deserves further investigation. 
Third, cardiovascular adverse effects were not formally evaluated in the present study. A 
large pharmaco-epidemiological study has shown a dose-dependent increase in the risk 
of sudden cardiac death (SCD) for patients treated with either classic or atypical 
antipsychotics, including OLZ (Ray et al., 2009). ZIP also has been found to be 
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associated with a high risk of QTc prolongation, which is an important predictor for 
torsade de pointes, ventricular fibrillation, and SCD (Strom et al., 2011). We postulate 
that lowering dosages of individual agents via combination regimens may be an 
effective strategy to reduce cardiovascular adverse effects, but this needs careful 
investigation. Finally, the baseline severity of psychotic symptoms varied significantly 
among the four groups. However, the use of baseline-to-endpoint changes and baseline 
total PANSS score as a covariate in the analysis of efficacy should help limit the impact 
of such baseline variations.  
 
Collectively, the present study demonstrated that combining ZIP and OLZ is superior to 
switching from OLZ to ZIP in controlling psychotic symptoms and reducing movement 
side effects without increasing the risk of metabolic syndrome. The combination of low-
dosed OLZ and ZIP could be considered as an option to replace an OLZ/ZIP switching 
therapy. We hope the present study will encourage further work to optimize 
antipsychotic polypharmacy regimens.  
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Legends for figures 
 
Fig. 1. Flowchart of screening and recruitment of study subjects with schizophrenia 
spectrum disorders (SSD). ZIP, ziprasidone; OLZ, olanzapine.    
 
Fig. 2. Changes from baseline in score on overall Positive and Negative Syndrome Scale 
(PANSS) (A) and its subscales on positiv2 (B), Negative symptoms (C) and 
general psychopharmacology (D) in patients with schizophrenia spectrum 
disorders (SSD). Statistical analysis results are presented in Table 3. ZIP, 
ziprasidone; OLZ, olanzapine.  
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Table 1. Baseline characteristics of patients with SSD 
Variables ZIP 
(n = 49) 
OLZ 
(n = 31) 
OLZ/ZIP 
(n = 35) 
OLZ+ZIP 
(n = 33) 
All 
(n = 148) 
Male, n (%) a 21 (42.9) 20 (64.5) 17 (48.6) 16 (48.5) 74 (50.0) 
Age (year) b 26.3 ± 7.2 27.4 ± 7.0 27.0 ± 5.5 26.9 ± 5.2 26.9 ± 6.4 
The illness duration (week) b 36.1 ± 48.5 39.4 ± 37.8 33.2 ± 36.9 42.9 ± 33.3 37.6 ± 40.3 
Having family members with 
mental illnesses, n (%) a 
7 (14.3) 5 (16.1) 6 (17.1) 6 (18.2) 24 (16.2) 
First-episode subjects, n (%) a 30 (61.2) 17 (54.8) 27 (77.1) 18 (54.5) 92 (62.2) 
Subtype of diagnosis, n (%) a      
Paranoid 38 (77.6) 23 (74.2) 28 (80.0) 25 (75.8) 114 (77.0) 
Hebephrenic 8 (16.3) 6 (19.4) 5 (14.3) 7 (21.2) 26 (17.6) 
Undifferentiated 3 (6.1) 2 (6.4) 2 (5.7) 1 (3.0) 8 (5.4) 
Overall PANSS score b 84.4 ± 12.0 80.1 ± 12.2 77.4 ± 10.7* 74.4 ± 7.0* 79.6 ± 11.4 
Body weight (kg) b 62.3 ± 11.5 62.5 ± 10.3 62.2 ± 10.9 62.1 ± 10.6 62.3 ± 10.8 
BMI (kg/m2) b 22.6 ± 3.8 22.2 ± 2.6 22.4 ± 2.4 22.0 ± 2.2 22.3 ± 3.0 
a
 Categorical data were analyzed using Chi-square (χ2) test. No statistically significant differences were 
observed among the four groups.  
b
 Continuous data are expressed as mean ± SD and examined using one-way analysis of variance 
(ANOVA), * p < 0.01 compared to ZIP group.  
SSD, schizophrenia spectrum disorders; ZIP, ziprasidone; OLZ, olanzapine; PANSS, the Positive 
and Negative Syndrome Scale; BMI, body mass index.  
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Table 2. Average doses of medications taken during the study a  
 
ZIP 
(n = 30) 
OLZ 
(n = 27) 
OLZ/ZIP 
(n = 27) 
OLZ+ZIP 
(n = 27) 
_________ANOVA_______ 
F              df              P 
OLZ (mg/day)  ----- 16.9 ± 1.4 9.5 ± 1.0* 9.9 ± 4.2* 76.932 2,79 <0.001 
ZIP (mg/day) 126.7 ± 18.5 ----- 126.9 ± 15.3 74.8 ± 37.9* 45.819 2,82 <0.001 
a
 Data are expressed as mean ± SD and examined using one-way analysis of variance (ANOVA), 
* p < 0.001 compared to monotherapy group. ZIP, ziprasidone; OLZ, olanzapine.  
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Table 3. Changes from baseline in score on overall PANSS and its subscales in patients with SSD a 
Variables ZIP (n = 49) 
OLZ 
(n = 31) 
OLZ/ZIP 
(n = 35) 
OLZ+ZIP 
(n = 33) 
_Overall analysis__  
F3,880              P 
Overall      21.261 <0.0001 
Week 1 -6.9 ± 9.1 -7.2 ± 11.4 -9.8 ± 7.8 -3.2 ± 14.2    
Week 2 -13.1 ± 8.3 -17.2 ± 15.5 -16.7 ± 7.5 -12.2 ± 15.5   
Week 4 -18.6 ± 8.1 -26.5 ± 14.8 -23.6 ± 8.4 -21.9 ± 17.0   
Week 8 -21.8 ± 8.8 -31.2 ± 16.2* -28.2 ± 9.5* -27.8 ± 13.3*   
Week 12 -25.1 ± 8.5 -34.7 ± 14.8* -30.9 ± 10.4 -33.9 ± 11.7*   
Positive symptoms     24.830 <0.0001 
Week 1 -2.3 ± 2.6 -2.5 ± 3.7 -2.7 ± 3.6 -1.6 ± 4.9   
Week 2 -4.3 ± 3.3 -5.3 ± 5.6 -4.8 ± 3.0 -4.0 ± 5.8   
Week 4 -6.2 ± 3.6 -8.7 ± 5.4 -6.4 ± 3.8 -7.0 ± 5.2   
Week 8 -7.4 ± 4.5 -9.7 ± 6.5 -7.3 ± 3.7 -8.1 ± 4.7   
Week 12 -7.3 ± 3.5# -10.7 ± 6.2 -7.4 ± 3.8#  -9.0 ± 5.3   
Negative symptoms     87.207 <0.0001 
Week 1 -0.9 ± 3.3 -2.1 ± 3.7 -3.2 ± 3.9  -0.4 ± 5.4   
Week 2 -2.5 ± 4.0 -3.7 ± 5.9 -4.6 ± 4.3 -2.6 ± 5.3   
Week 4 -4.1 ± 3.7 -5.9 ± 3.9 -6.1 ± 4.8 -4.9 ± 5.2   
Week 8 -3.9 ± 3.4 -7.0 ± 4.2* -7.3 ± 4.9* -6.7 ± 5.0*   
Week 12 -5.1 ± 3.0 -8.7 ± 3.9* -7.7 ± 4.8* -9.4 ± 4.7*   
General psychopathology     8.495 <0.0001 
Week 1 -3.8 ± 6.5 -2.5 ± 8.0  -3.9 ± 3.3 -1.3 ± 7.6   
Week 2 -6.3 ± 5.0 -8.2 ± 10.3 -7.3 ± 3.2 -5.5 ± 7.5   
Week 4 -8.3 ± 5.4 -11.9 ± 9.5 -11.1 ± 3.7 -10.0 ± 8.4   
Week 8 -10.4 ± 5.5 -14.5 ± 9.5 -13.6 ± 4.9 -13.1 ± 6.3   
Week 12 -12.7 ± 5.3 -15.3 ± 9.4 -15.8 ± 5.9 -15.5 ± 7.7   
a
 Data are expressed as mean ± SD. Overall statistical significance was analyzed using a linear mixed-
effect model analysis. Between-group differences were further evaluated using one-way analysis of 
variance (ANOVA). * p < 0.05 compared to ZIP group; # p < 0.05 compared to OLZ group; Gp = 
0.013 compared to OLZ/ZIP group. PANSS, the Positive and Negative Syndrome Scale; SSD, 
schizophrenia spectrum disorders; ZIP, ziprasidone; OLZ, olanzapine.  
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Table 4. Baseline-to-endpoint changes in weight gain and metabolic variables in patients with SSD a 
Variables ZIP (n = 30) 
OLZ 
(n = 27) 
OLZ/ZIP 
(n = 27) 
OLZ+ZIP 
(n = 27) 
____ANOVA____ 
F3,108           P 
Net weight gain 
(kg)  
-0.1 ± 2.3* 3.9 ± 2.6 0.0 ± 1.7* 0.8 ± 1.8* 20.575 <0.001 
Net change in 
BMI (kg/m2) 
0.0 ± 0.8* 1.4 ± 1.0 0.0 ± 0.6* 0.3 ± 0.6* 19.272 <0.001 
Glucose (%) 6.3 ± 13.0* 19.2 ± 19.7 8.3 ± 10.8* 9.7 ± 20.0* 3.307 0.023 
TG (%) 42.2 ± 138.4 66.9 ± 83.8 26.2 ± 59.8 32.1 ± 62.1 1.027 0.384 
Cholesterol (%) -5.8 ± 25.5* 20.0 ± 30.8 -0.5 ± 26.2* 1.0 ± 27.5* 4.551 0.005 
HDL (%) 5.6 ± 35.4 -20.4 ± 34.3 10.0 ± 72.4 -6.6 ± 29.4 2.364 0.075 
LDL (%) 14.4 ± 50.2 32.6 ± 62.7 11.8 ± 50.9 31.4 ± 74.3 0.908 0.440 
TG/HDL (%) 49.7 ± 142.0* 157.8 ± 201.7 44.5 ± 97.2* 60.4 ± 94.5* 3.907 0.011 
a
 Data are expressed as mean ± SD and evaluated using one-way analysis of variance 
(ANOVA), followed by Student-Newman-Keuls method. * p ≤? 0.043 compared to OLZ 
group. SSD, schizophrenia spectrum disorders; ZIP, ziprasidone; OLZ, olanzapine; TG, 
triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
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Table 5. The incidence of major adverse events occurred in patients with SSD, the proportion with different 
severity of ESRS-measured extrapyramidal symptoms and the proportion required to use hypnotics/anxiolytics 
for insomnia and anticholinergic agents for extrapyramidal symptoms, n (%) a 
Adverse event 
ZIP 
(n = 49) 
OLZ 
(n = 31) 
OLZ/ZIP 
(n = 35) 
OLZ+ZIP 
(n = 33) χ
2
 value p value 
Any  32 (65.3) 22 (71.0) 28 (80.0) 8 (24.2) 25.683 <0.001 
Dizziness 7 (14.3) 2 (6.5) 3 (8.6) 0 5.546 0.136 
Muscle rigidity 15 (30.6) 10 (32.3) 10 (28.6) 1 (3.0) 8.381 0.039 
Tremor 18 (36.7) 9 (29.0) 10 (28.6) 2 (6.1) 9.926 0.019 
Akathisia 8 (16.3)  3 (9.7) 7 (20.0) 2 (6.1) 3.550 0.314 
Nausea/vomiting 6 (12.2) 2 (6.5) 4 (11.4) 1 (3.0) 2.612 0.455 
Constipation 9 (18.4) 4 (12.9) 8 (22.9) 3 (9.1) 2.787 0.426 
Insomnia 15 (30.6) 6 (19.4) 13 (37.1) 4 (12.1) 6.864 0.076 
Dry mouth 6 (12.2) 4 (12.9) 3 (8.6) 2 (6.1) 1.196 0.754 
ESRS     16.649 0.011 
None to mild 16 (32.6) 15 (48.4) 9 (25.7) 23 (69.7)   
Moderate 24 (49.0) 12 (38.7) 20 (57.1) 8 (24.2)   
Severe 9 (18.4) 4 (12.9) 6 (17.2) 2 (6.1)   
The use of medication to 
treat side effects  
      
Hypnotics/ anxiolytics 11 (22.4) 7 (22.6) 9 (25.7) 5 (15.2) 1.198 0.754 
Anticholinergic 13 (26.5) 9 (29.0) 12 (34.3) 11 (33.3) 0.758 0.859 
a
 Data were analyzed using Chi-square (χ2) test (df = 3). SSD, schizophrenia spectrum disorders; 
ZIP, ziprasidone; OLZ, olanzapine; ESRS, extrapyramidal symptom rating scale.  
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Fig. 1 
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